MSLN and neoplasm: While mesothelin-specific CAR-T cells were capable of eradicating tumor cells with homogenous antigen expression in an immunocompetent mouse model, complete remission could not be attained under conditions of heterogeneous antigen expression with 10% of inoculated tumor cells staining negative for mesothelin [103].